MZE001 is currently being evaluated as a potential oral treatment for patients with Pompe disease, as well as other glycogen storage disorders. Currently, the drug is in Phase I stage of its clinical ...
Glycogen storage disease type 1a (von Gierke disease ... The infant was started on dietary treatment with frequent meals, restriciton of glucose and lactose, two meals with uncooked starch ...